What is Maze Therapeutics, Inc. Common Stock (MAZE) stock price today?

Maze Therapeutics, Inc. Common Stock (MAZE) currently trades at $26.58 per share. The stock has a market capitalization of $1.42B and a P/E ratio of —x.

Is MAZE stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Maze Therapeutics, Inc. Common Stock has a Smart Value Score of 26/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is -0.44.

Is Maze Therapeutics, Inc. Common Stock financially healthy?

Maze Therapeutics, Inc. Common Stock's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of -0.44 places it in the distress.

MAZE

Maze Therapeutics, Inc. Common Stock

NASDAQ: MAZE · HEALTHCARE · BIOTECHNOLOGY

$26.58

+3.50% today

Updated 2026-04-30

Market cap

$1.42B

P/E ratio

—

P/S ratio

501.65x

EPS (TTM)

$-3.05

Dividend yield

—

52W range

$8 – $54

Volume

0.9M

Market cap

$1.42B

P/E ratio

—

P/S ratio

501.65x

EPS (TTM)

$-3.05

Dividend yield

—

52W range

$8 – $54

Volume

0.9M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

5.3

Quality

C+

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

-0.4

Altman Z-Score

Distress

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$63.55

+139.09%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy11 Buy0 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Piotroski 2/9 — weak financial health

- Altman Z -0.44 — distress zone

- Thin margins at 0.00%

- Negative free cash flow $-27.76M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$167.50M	$0.00	$0.00
Net income	$-114.94M	$-100.42M	$52.23M	$-131.12M	$-34.57M
EPS	—	—	—	—	$-3.05
Free cash flow	$-101.17M	$-87.27M	$74.81M	$-112.73M	$-27.76M
Profit margin	—	—	31.18%	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
MAZE	$1.42B	26	4.3	3.0	5.0	5.3	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$336.47B	54	5.3	5.5	7.3	4.8	+42.09%	Buy
AZN	$287.11B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Maze Therapeutics, Inc. Common Stock trades at $26.58. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.44, it sits in the distress.

Frequently asked questions

What is Maze Therapeutics, Inc. Common Stock's stock price?

Maze Therapeutics, Inc. Common Stock (MAZE) trades at $26.58.

Is Maze Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 26/100 (Grade F, Strong Sell).

What is the price target of Maze Therapeutics, Inc. Common Stock (MAZE)?

The analyst target price is $63.55, representing +139.1% upside from the current price of $26.58.

Piotroski F-Score?

2/9 — weak financial health.

Altman Z-Score?

-0.44 — distress.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio501.65x

ROE-47.50%

Beta—

50D MA$37.61

200D MA$31.96

Shares out0.06B

Float0.03B

Short ratio—

Avg volume0.9M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

MAZE vs LLY →MAZE vs JNJ →MAZE vs ABBV →Stock screener →